Increasing Patient eCOA Compliance: Cara Therapeutics Increased Compliance And Reduced Burden On Study Teams With Suvoda

Cara Therapeutics is a commercial-stage biopharmaceutical company dedicated to transforming the lives of patients suffering from chronic pruritus—a debilitating condition characterized by persistent itching. With a strong focus on innovation, and in collaboration with Suvoda, Cara Therapeutics achieved a significant milestone in their clinical research efforts. By leveraging Suvoda’s advanced eClinical solutions, the company saw a remarkable increase in patient compliance with electronic Clinical Outcome Assessments (eCOA) and IRT in two pivotal pruritus studies. This improvement not only accelerated the study submission process but also enhanced operational efficiency and provided greater visibility into trial progress.

If you're looking to streamline your clinical trials and boost patient engagement, discover how Suvoda can help you achieve similar success.